The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Pfizer Sales Reps Told to Avoid Doctor Visits, Stay at Home amid Coronavirus Woes
Pfizer Japan will have all its employees who work outside the office including sales reps refrain from visiting medical institutions and other clients as much as possible from February 28 through March 13 as a measure to prevent the spread…
To read the full story
Related Article
- Pfizer Japan Further Extends Work-from-Home through May-End
April 23, 2020
- Pfizer Japan Extends Work-from-Home through May 6
April 7, 2020
- Pfizer Japan Extends Voluntary Ban on Doctor Visits to April 10
March 27, 2020
- Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
March 13, 2020
- Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus
March 11, 2020
- Sawai Refrains from Sales Reps' Doctor Visits Through March 13
March 4, 2020
- Japan Drug Makers Fearing Manufacturing Crisis as Coronavirus Spreads
February 27, 2020
- Drug Makers in Japan Upping Coronavirus Measures; Takeda Switches to Online Interviews for New R&D Hires
February 26, 2020
- Astellas, MSD Follow Suit to Boost Measures to Protect Employees from Coronavirus Infection
February 21, 2020
- Drug Makers in Japan Urging Staffers to Work at Home, Shun Rush-Hour Commuting amid Coronavirus Fears
February 19, 2020
BUSINESS
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
- Dayvigo Wins Triple Crown in November HP Promotion List: Intage
December 26, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…